Lexington Partners L.P. Purchases New Position in Medline $MDLN

Lexington Partners L.P. purchased a new stake in Medline (NASDAQ:MDLN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 134,232 shares of the company’s stock, valued at approximately $5,638,000. Medline comprises about 1.7% of Lexington Partners L.P.’s portfolio, making the stock its 3rd largest holding.

A number of other institutional investors have also recently made changes to their positions in MDLN. Perigon Wealth Management LLC bought a new position in shares of Medline in the 4th quarter valued at about $211,000. SteelPeak Wealth LLC bought a new stake in Medline in the fourth quarter worth about $441,000. Sound Income Strategies LLC bought a new stake in Medline in the fourth quarter worth about $25,000. Massachusetts Financial Services Co. MA bought a new stake in Medline in the fourth quarter worth about $429,544,000. Finally, Baillie Gifford & Co. bought a new stake in Medline in the fourth quarter worth about $437,236,000.

Analysts Set New Price Targets

Several brokerages have issued reports on MDLN. BNP Paribas Exane decreased their price objective on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Wells Fargo & Company raised their price objective on shares of Medline from $42.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Tigress Financial raised their price objective on shares of Medline from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Barclays decreased their price objective on shares of Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Stifel Nicolaus set a $55.00 price objective on shares of Medline in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.54.

Medline Stock Performance

Shares of NASDAQ:MDLN opened at $34.47 on Thursday. The stock’s 50 day moving average is $41.79. Medline has a one year low of $32.81 and a one year high of $50.88.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. Sell-side analysts anticipate that Medline will post 1.5 earnings per share for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.